Home/Pipeline/Lung Cancer Detection

Lung Cancer Detection

Lung Cancer

Clinical ValidationActive

Key Facts

Indication

Lung Cancer

Phase

Clinical Validation

Status

Active

Company

The eNose Company

About The eNose Company

The eNose Company is pioneering breath analysis for medical diagnostics using its proprietary electronic nose technology. It has advanced its lead program for detecting lung cancer and COVID-19 into clinical validation and commercialization phases, with a broader pipeline targeting asthma, COPD, and other conditions. As a publicly traded company on Euronext Access Paris, it operates in a high-growth digital diagnostics market but faces risks related to clinical validation, reimbursement, and competition from established diagnostic methods and emerging AI-driven platforms.

View full company profile

Therapeutic Areas

Oncology Pulmonology Infectious Diseases

Other Lung Cancer Drugs

Drug	Company	Phase	Status
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active
TEC-001 + Keytruda	Teclison	Phase 2	Active